Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)
Fast, easy summary view of NICE guidance on 'early and locally advanced breast cancer'
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat
NICE has assessed the MammaPrint, Oncotype DX, IHC4 and Mammostrat to help the NHS decide whether to use these products.
MammaPrint, Oncotype DX, IHC4 and Mammostrat are tests for certain genes or proteins found in breast cancer tumours. Testing for the levels of these may give healthcare professionals an indication of how a tumour might develop, and therefore help in treatment planning.
NICE has said that Oncotype DX is recommended to help make decisions about chemotherapy after surgery in some people with oestrogen receptor positive (ER+), lymph node negative (LN−) and human epidermal growth factor receptor 2 negative (HER2−) early breast cancer. Your healthcare professional should discuss with you whether this might be right for you.
NICE has said that MammaPrint, IHC4 and Mammostrat should only be used in research. This is because it’s not certain how much benefit they can provide.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: early and locally advanced breast cancer
- None found
This page was last updated: 26 September 2013
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.